bluebird bio(BLUE) ZACKS·2025-05-14 23:55Core Viewpoint - Bluebird Bio reported a quarterly loss of $2.66 per share, which was better than the Zacks Consensus Estimate of a loss of $3.60, and significantly improved from a loss of $7.20 per share a year ago, indicating a positive earnings surprise of 26.11% [1] Financial Performance - The company posted revenues of $38.71 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 17.98%, but showing an increase from $18.57 million in the same quarter last year [2] - Over the last four quarters, Bluebird has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Bluebird shares have declined approximately 60.3% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] - The current Zacks Rank for Bluebird is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.20 on revenues of $68.8 million, and for the current fiscal year, it is -$15.19 on revenues of $282.8 million [7] - The trend of estimate revisions for Bluebird is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Bluebird belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]